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Functional outcomes in early (T1/T2)
supraglottic cancer: a systematic review
Benjamin van der Woerd1 , Krupal B. Patel2, Anthony C. Nichols1, Kevin Fung1, John Yoo1 and S. Danielle MacNeil1*

Abstract
Objectives: Organ preserving surgery (OPS) and radiotherapy (RT) are both accepted treatment options for early
stage supraglottic cancer (SGC). Radiation has supplanted surgery in most cases, because of the perception that
surgery results in poorer functional outcomes. However, evidence suggests that OPS with a neck dissection may be
associated with improved survival. Our objective was to conduct a systematic review of the literature to compare
functional outcomes of OPS and RT for early SGC.
Methods: We searched Medline, EMBASE and Cochrane Central Register of Controlled Trials to identify studies.
Studies were included if they reported functional outcomes on 10 or more patients with early stage SGC treated
with radiation or OPS, including open partial laryngectomy, transoral laser microsurgery (TLM) or transoral robotic
surgery (TORS). Two reviewers independently screened articles for relevance using pre-determined criteria.
Results: From 7720 references, we included 10 articles (n = 640 patients). 50% (n = 320) of patients were treated
with surgery. Three head-to-head RT versus OPS papers were included, however different outcome measures were
used for each group. Intractable aspiration management (including total laryngectomy or permanent tracheostomy)
following OPS was reported in five papers representing 186 patients; the definitive intractable aspiration
management rate was 2.6% (95% CI 1.0–6.8%). Four papers reported permanent G-tube rate for the surgical group
(n = 198), calculating a rate of 5.3% (95% CI 2.6–10.5%), this was not reported for the RT group in any papers. One
study reported quality of life. Two studies reported objective voice measures.
Conclusions: This systematic review revealed a paucity of objective measures and significant data heterogeneity,
rendering the comparison of functional outcomes following OPS versus RT for early SGC limited. Future research
should include objective measures of functional outcomes including laryngectomy rate, g-tube rate, tracheostomy
dependence, quality of life, and voice quality measures.
Keywords: Early stage, Supraglottic squamous cell carcinoma, Supraglottic SCC, Outcomes, Systematic review,
Functional outcomes

Introduction
Early stage supraglottic squamous cell carcinoma (SSCC)
includes T1 tumours, isolated to one subsite of the supraglottis with normal vocal cord function, or T2 tumours,
involving more than one subsite of the supraglottis, glottis,
or surrounding tissue, without evidence of regional disease
spread [1]. A recent study of nearly 160,000 laryngeal cancer SCC patients in the United States, found the incidence
of SSCC to account for one third of laryngeal cancers [2].
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Laryngeal cancers are the most common malignant lesions of the head and neck, with an estimated 13,150 new
laryngeal cancers per year [3].
The recommendations from the National Comprehensive Cancer Network (NCCN) guidelines for treatment of
early stage SSCC include both organ preservation strategies – radiation (RT) or organ preservation surgery
(OPS) with or without a neck dissection [3, 4]. Despite
small tumour sizes, 5-year survival for early stage SSCC is
64%, and oncologic outcomes have not improved over the
past 30 years [2, 5–8]. This is hypothesized to be a result
of the robust lymphatic supply to the supraglottis leading
to higher rates of occult metastases to regional and distant
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sites. When comparing the relative 5-year survival from
1985 to 1987 to 1994–1996, there was a decline from
52.2 to 47.3%. Reviewing the data from the National
Cancer Database, the largest decline was identified in patients with T1 N0-T2 N0 disease. A recent meta-analysis
by Patel et al. (2018) examining survival in early stage
supraglottic SCC suggested that primary surgery may result in decreased disease specific survival (OR 0.43, 95%
CI 0.31–0.60) and overall mortality (OR 0.40, 0.29–0.55)
when compared with primary radiotherapy [9].
There are a limited number of studies, with no previous meta-analysis, that have compared the functional
outcomes between primary surgery and primary radiotherapy for early stage SSCC. Much of the available data
focuses on survival outcomes for the two treatment modalities [7–17]. There are no prospective clinical trials,
and the majority of the studies reported are small and
retrospective in design. Our objectives were to systematically review the literature to find all the relevant studies
about the functional outcomes for surgery and radiation
for early stage SSSC, synthesize the results and perform
meta-analyses where possible.

Methods
A systematic review protocol was developed a priori to ensure the objectives and aims were outlined from the outset.
Computerized bibliographic databases: Medline, EMBASE
and Cochrane Central Register of Controlled Trials were
searched to identify studies. English language records were
included from January 1990 to October 2018. The search
strategy was designed by three authors (B.V.W., K.B.P.
and S.D.M.) and an experienced librarian.
Randomized controlled trials, head-to-head comparative
studies, observational studies, and case series that included 10 or more patients were reviewed. Single arm
studies that reported functional results of organ preservation surgeries or radiotherapy as single modality therapy
were included in the review. Studies on organ preserving
surgeries, including open partial laryngectomy, transoral
laser microsurgery (TLM) or transoral robotic surgery
(TORS), with and without neck dissection were included.
The study population was limited to patients aged 18
and older, diagnosed with early stage supraglottic SCC
(Tis, T1 N0, T2 N0). We excluded studies where functional results for patients with advanced T stage or node
positive disease were grouped into the results and could
not be reliably differentiated. We also excluded studies
where functional outcomes for patients with early supraglottic cancers were combined with early glottic cancers.
Included studies were assessed for the following functional outcomes: aspiration; gastrostomy tube dependence;
objective voice outcomes; and quality of life measures.
Titles, abstracts, and full texts of the studies were
reviewed independently by two authors (B.V.W. and
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K.B.P.). Disagreements were resolved by consensus.
Inter-observer agreement was analyzed with Cohen’s kappa.
Titles were screened for the keywords: “squamous cell
carcinoma” and “supraglottic”, or “supraglottis”, or “glottic”,
or “glottis”, or “larynx”, or “laryngeal”. All study abstracts
that met the eligibility criteria were then screened individually. The full text of studies that met inclusion criteria were
then reviewed. The Newcastle-Ottawa Quality Assessment
Scale for Cohort Studies was used to determine the quality
of the studies (Table 2) [18]. Relevant data was extracted
using a standardized data extraction form. Not all studies
contained data for each of the outcome measures.
Review Manager 5.3 and Comprehensive Meta-Analysis
applications were used for statistical analysis. Dichotomous outcomes were compared using odds ratios (OR) or
weighted incidence rates and 95% confidence intervals
(CI). Heterogeneity across the studies was evaluated by
the chi-square statistic and significance was set at p < 0.05.
The I2 test was used to measure the extent of inconsistency across the results.
A random effects model was used to allow for differences in the treatment effects from study to study. The
Z statistic was used to test for overall pooled effect and
significance was set at p < 0.05.

Results
The search strategy produced 7720 records. After duplicate records were removed from the search, 5218 unique
records remained. After reviewing the titles, 1187 abstracts were deemed appropriate for abstract review. Following abstract review, 115 studies were appropriate for
full text review. Ten studies met the final inclusion criteria
after reviewing the full text. CONCLUSIONS:
There is an overall paucity of literature available regarding functional outcomes in the treatment of early
stage SSCC patients, the majority of which is moderate
in overall quality and retrospective in nature. The majority of the data does not reflect the treatment algorithms of today, with the introduction of focused
radiation therapies and endoscopic surgical approaches.
Changes to treatment algorithms have not been reflected
in head-to-head studies examining the functional outcomes. The outcome measures reported have significant
heterogeneity in the current literature, which limits the
ability to draw definitive conclusions.
Moving forward, we propose that aspiration, intractable aspiration intervention, permanent gastrostomy
tube requirements, and objective quality of life scales as
objective measures that should be included in future research on this topic. Future studies and research should
include well designed prospective trials with rigorous
reporting of outcome measures.
Figure 1 Illustrates the PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) flow
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Fig. 1 PRISMA Flowchart

chart to identify the appropriate studies. Kappa statistic
for the agreement at the abstract screening stage was
0.61 (95% CI 0.37–0.85) indicating moderate agreement.
Study characteristics and methodologic quality

There were no randomized controlled trials comparing
the functional outcomes of primary surgery versus radiation. Of the 10 studies included in the analysis, 6 were
retrospective cohort studies, 4 were case series. There
were no prospective studies included. There were 320
patients treated with OPS, including open partial laryngectomy, transoral laser microsurgery (TLM) or transoral robotic surgery (TORS). For the RT arm, there
were 320 patients. Altogether, 640 patients were analyzed from 10 studies. There were 6 patients with early
SSCC where the treatment modality was not specified
and could not be included in the analyses. Characteristics of the included studies are summarized in Table 1.
Overall, the quality of the included studies was moderate, this was for a variety of reasons, including no reference group (surgery or radiation arm only), short or
unreported length of follow up, and unaccounted for
patients. Table 2 summarizes the quality of the individual studies.

Aspiration

Aspiration was deemed a primary functional outcome
measure of assessment. It was reported in 5 studies [11,
14, 19–21]. In one paper, this was evaluated under direct
visualization with a functional endoscopic examination
of swallowing, where the authors documented liquid
penetration. The remainder of the papers reported patients with clinically evident late aspiration, and sequelae
such as aspiration pneumonia. In the surgical arm, 9 out
of 252 patients were reported to experience aspiration,
for a pooled aspiration rate of 3.7% (95% CI 1.9–6.9%)
(Fig. 2). In the RT arm, aspiration is reported in 15 out
of 198 patients, for a pooled aspiration rate of 14.5%
(95% CI 9.1–22.5%) (Fig. 3). The odds ratio is 1.23 (95%
CI 0.14–10.86) (Fig. 4).
Intractable aspiration management

In many of the studies, rate of functional laryngectomy
and permanent tracheostomy dependence was reported.
These statistics included some, but not all, of the patients who experienced late complications associated
with aspiration events. This was reported in 5 studies,
accounting for 186 surgical patients and 198 radiation
patients. The pooled event rate for intractable aspiration
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Table 1 Study Characteristics
Study ID

Location

Dates of Accrual

Age Mean (range)

OPS

RT

Stage

Ambrosch 2018

Italy

2002–2012

Medianc 62 (33–88)

27

0

T1 N0 (n = 8)
T2 N0 (n = 19)

Bhattacharyya 2014

India

2006–2009

Medianc 59 (31–80)

0

10

T1 N0 (n = 1)
T2 N0 (n = 9)

Carta 2018

Italy

2010–2017

Mean 61.8 (43–84)

27

0

T1 N0 (n = 11)
T2 N0 (n = 16)

Chiesa Estomba 2015

Spain

2009–2012

Mean 64 (45–88)

72

0

T1 N0 (n = 44)
T2 N0 (n = 28)

Chun 2010

South Korea

1991–2005

Mean 65.5

25

10

T1 N0 (n = 14)
T2 N0 (n = 21)

Karatzanis 2010

Germany

1970–2004

Mean 60 (36–83)

78

0

T1 N0 (n = 29)
T2 N0 (n = 49)

Mendenhall 1996

USA

1964–1992

NR

0

99

T1b (n = 18)
T2 (n = 81)

Oridate 2009

Japan

2006–2007

Medianc 76 (45–90)

NRa

11

T2 N0 (n = 11)

Orus 2000

Spain

1984–1996

Mean 60.5

25

90

T1 N0 (n = 38)
T2 N0 (n = 77)

Spriano 1997

Italy

1983–1992

NR

66

100

T1 N0 (n = 112)
T2 N0 (n = 54)

a

6 patients not accounted for in the results, bnodal staging not reported, cMedian age presented

management in the surgical arm is 2.6% (95% CI 1.0–
6.8%) (Fig. 5). The pooled event rate for the RT arm is
16.8% (95% CI 10.8–25.0%) (Fig. 6). The odds ratio comparing the two groups is 1.14 (95% CI 0.04–33.45)
(Fig. 7).

Permanent gastrostomy tube and swallowing dysfunction

The rate of permanent gastrostomy tube was reported in
four studies for the OPS group. This accounted for 198
patients. This outcome measure was not reported for
the radiation group in any of the studies. The pooled
event ratio for permanent gastrostomy tube dependence
is 5.3% (95% CI 2.6–10.5%) (Fig. 8).
Table 2 Newcastle-Ottawa quality assessment scale for cohort
studies
Study

Selection Comparability Outcomes Total Score

Ambrosch 2018e

3
b

2

3

8

Bhattacharyya 2014

3

2

3

8

Carta 2018

2

1

3

6

Chiesa Estomba 2015

3

2

3

8

Chun 2010a

4

1

2

7

Karatzanis 2010

3

2

3

8

Mendenhall 1996c

3

0

1

4

Oridate 2009

4

0

1

5

Orus 2000d

4

1

1

6

Spriano 1997

4

2

3

9

b

c,d

a

length of follow-up not reported, bsurgery only cohort, cshort follow up period,
d
not all patients accounted for, eradiation only cohort

Additionally, Chun et al. compared OPS to RT with
respect to functional outcomes of swallowing and
speech. To evaluate swallowing, patients underwent a
functional endoscopic examination of swallowing (FEES)
using videoesophagofluoroscopy. The researchers looked
specifically for evidence of aspiration. Liquid aspiration
was identified 6% of patients in the OPS group (n = 1).
There was no identified liquid aspiration in the RT cohort [11].
Quality of life and voice outcomes

Quality of life data was reported in one study. Another
study reported objective voice outcome measures. Oridate
et al. compared VRQOL, VHI-10, and GRBAS scores for
T2 N0 SSCC against T1a, T1b, and T2 N0 glottic carcinomas and found no significant differences in functional
outcomes [22].
Chun et al. used stroboscopy and acoustic waveform analysis to objectively evaluate voice outcomes. Abnormalities
were in mucosal waveforms were identified 13% of the OPS
cohort (n = 2) and 20% of the RT group (n = 2). These findings were not statistically significant [11].

Discussion
To our knowledge, this is the first systematic review evaluating the functional outcomes of surgery versus radiotherapy for early-stage SSCC. All studies that met inclusion
criteria were retrospective in design and there were 3
head-to-head comparisons of surgery versus radiation.
Aspiration events, management of intractable aspiration,
and permanent gastrostomy tubes are some of the major
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Fig. 2 Pooled event rate of aspiration for early stage SSCC treated with organ preservation surgery

indications of laryngeal function. There was insufficient
data to thoroughly meta-analyze the two modalities with
respect to these outcome measures. Furthermore, objective voice outcomes were available in just two studies.
Quality of life measures were only found in one included
paper.
Aspiration events were reported, in many cases, with
little additional information. In some studies, these were
clinically evident respiratory events, such as aspiration
pneumonias that occurred late in the post-operative
course, others reported only the number patients that
experienced aspiration. Aspiration events are reported in
50% of studies (n = 5), 2 of which were head-to-head
comparisons.
For intractable aspiration intervention, there was data
from both the surgical and radiation cohorts from
multiple studies. This was reported as permanent tracheostomy dependence or conversion to a functional total
laryngectomy. We calculated pooled event rates as well
as pooled odds ratio. From the current data available,
there is no strong evidence to suggest there is a difference between the two modalities with respect to this
outcome measure.
With respect to permanent gastrostomy tube rate,
there was no available data for the radiation cohort. Four
papers reported this outcome measure for the surgical
group (n = 198 patients). As a result, we were unable to
make comparisons across the two treatment modalities.
Subjective and objective measures of voice outcome
were sparsely and inconsistently reported. Quality of life
measures were found in just one study, which actually
compared T2 N0 supraglottic cancers to early glottic
cancers.

Surgery and radiotherapy for early stage SSCC

Several factors are important in considering treatment
options for patients with early laryngeal cancer. Survival
outcomes are obviously at the forefront. While there is
no RCT data comparing survival outcomes of patients
with early SSCC, a 2016 meta-analysis by Patel et al.
studying early stage SSCC suggests that patients who
undergo primary surgery have better survival than those
who underwent primary radiotherapy [8]. Laryngectomy
rate is another important consideration, as most patients
with early stage laryngeal cancer are candidates for
organ preservation treatment. Finally, in the presence of
equivalent survival for two treatment modalities, functional outcomes are important to assess in comparing
treatment options.
Over the last 40 years the treatment of early stage laryngeal cancer has evolved [23, 24]. Surgery, in the form
of open partial laryngectomy, was initially popular however many patients had poor functional outcomes including aspiration and impaired base of tongue and
laryngeal movements leading to swallowing dysfunction
[25]. Radiation then took over as the primary treatment
modality for early stage laryngeal cancer, with the goal of
mitigating many of the functional problems associated
with open partial laryngectomy. However, radiation is
not without its own side effects. In addition, minimally
invasive surgical techniques including TORS and TLM
are increasingly being used for early stage SSCC [23, 24],
raising the question of whether the functional outcomes
with TORS and TLM may be better than radiation.
Unfortunately, there are very few studies reporting the
functional outcomes of TORS and TLM for early stage
supraglottic cancer.

Fig. 3 Pooled event rate of aspiration for early stage SSCC treated with radiation
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Fig. 4 Forest Plot of comparison between organ preservation surgery and radiation with respect to aspiration events

There are several advantages of RT. It preserves the
laryngeal structures, it is generally well tolerated by
patients, and increases surgical exposure to achieve excellent oncologic outcomes [26–29]. Radiation provides an
effective treatment modality for patients not considered
candidates for OPS due to their comorbid medical conditions. One of the disadvantages in treating early stage
SSCC with RT, is that these patients are at high risk for
developing a second primary and local regional recurrence
[5, 6, 30]. If radiation is used as the primary treatment modality, most patients can only be salvaged with surgery,
and, in the case of recurrent or new laryngeal cancer, the
treatment is almost always total laryngectomy.
Surgical approaches include open surgery or transoral
surgical approaches, including laser (TLM) and robotic
(TORS). Organ-preserving surgery, both open and endoscopic approaches, offer several advantages over RT. As
mentioned, patients with SSCC have reasonable 5-year
overall survival rates, albeit with an increased risk of developing second primary aerodigestive tract malignancy
[5, 6, 30]. Surgery can therefore be utilized as the first line,
and, in the setting of recurrence, radiation can be used as
salvage therapy. An additional advantage of surgery is the
cost benefit of surgical intervention over radiotherapy
[31, 32]. Furthermore, surgical management with a
neck dissection provides the opportunity to identify occult metastasis; an important consideration given that
up to 30% patients with SSCC may have occult nodal
metastasis [32]. Identification of occult metastasis allows for accurate staging of patients, and subsequently
treatment with multimodality therapies.

Dombree et al. analyzed the cost of open supraglottic
laryngectomy, TLM, and TORS in a Belgian model.
Their study suggests the cost of open supraglottic laryngectomy similar to that of TLM in upfront surgical costs
[31]. TORS tends to be more expensive primarily due to
purchase and maintenance costs [31]. This study did not
account for in-hospital costs such as length of admission, complications or readmission rates. With regard to
glottic cancers, a cost analysis was carried out for a
Canadian model comparing TLM to radiotherapy. This
showed TLM to be a more cost-effective treatment
option [33].
There are also disadvantages of surgery, including risk
of general anesthetic, particularly in patients with comorbidities, bleeding, and infection. Pharyngocutaneous fistula, dysphagia and permanent tracheostomy dependence
are specific risks of supraglottic laryngectomies. A criticism of OPS are the associated poor functional outcomes
[25]. However, newer surgical techniques including TLM
and TORS have gained popularity recently, and hold
several advantages over open surgery and RT. In one
study, TLM was compared to open surgery, resulting in
reduced incidence of permanent gastrostomies and
tracheostomies [20]. Since the introduction of TLM by
Strong and Jako, there have been several reports investigating the role of TLM for supraglottic laryngectomy
[34–48]. With respect to TORS, the majority of the studies report on all stages of supraglottic SCC [20, 43, 48–
59]. With that in mind, long-term tracheostomy and gastric feeding tube rates range from 0 to 20% in patients
treated with TORS [49, 52, 55]. None of the studies

Fig. 5 Pooled event rate of management of intractable aspiration for early stage SSCC treated with organ preservation surgery
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Fig. 6 Pooled event rate of definitive aspiration management for early stage SSCC treated with radiation

included in this systematic review examined the functional
outcomes of TORS.
Strengths

There are several strengths to this review. To our knowledge, this is the first comprehensive review of all available
literature comparing functional outcomes between surgery
versus radiation for patients with early stage SSCC. It was
designed, conducted and reported in accordance with
published guidelines (PRISMA) and the study protocol, as
well as search strategy, was outlined a priori. A comprehensive search strategy was undertaken and led to the
review of 5218 unique citations of which ten studies met
our inclusion criteria. This resulted in the analysis of a
large number of patients with early stage SSCC (n = 640).
Limitations

As with all systematic reviews, the strength of the conclusions that can be drawn from this study depend on the
quality of the primary studies. The included studies were
evaluated with the Newcastle-Ottawa Scale for Assessing
Cohort Studies, most of which were of moderate in overall
quality. Next, although we only included studies published
from 1990 forward, some of the studies in our review included patients treated well before that time period. This
broad recruitment period includes many patients where
treatment algorithms may not reflect today’s standards.
Given the improvements in medical imaging, some patients
may have had regional nodal disease which was not evident
on the available scans, therefore reflecting more advanced
disease. Furthermore, many of the current treatment

options, such intensity modulated radiotherapy (IMRT),
TLM, and TORS were not in clinical practice prior to 1990.
The types of radiation and protocols used were not clearly
outlined in the studies included. As well, given the broad
recruitment periods for some of these studies, different
radiotherapy protocols would have been offered to the
patients according to the available therapies at that time.
All 10 studies that met the inclusion criteria were
retrospective study designs and there were no randomized controlled trials. Retrospective studies have inherent
biases including selection biases. Patient’s with medical
comorbidities may not have been deemed appropriate
surgical candidates and only offered radiotherapy, which
may not be reflected in the results.
Significant heterogeneity was noted between the outcome measures of the included studies. In the surgical
group, not all patients may have received the same type or
extent of surgery, including elective neck dissections,
TLM, and TORS operations. We only considered English
language studies for our systematic review, which limited
the number of titles screened and studies included, however, the effect of this would likely be small.
The heterogeneity of the functional outcomes reported
limited our ability to meta-analyze the data. Additionally,
many of the outcomes were sparsely reported or reported for
only one of the arms of study, either OPS or RT. The overall
paucity of data limits our ability to draw conclusions.
Given the lack of high level evidence guiding the optimal management of early stage supraglottic cancer and
potential biases of retrospective studies, a head to head
comparison between newer modalities such as TLM and

Fig. 7 Forest Plot of comparison between organ preservation surgery and radiation with respect to management of intractable aspiration with
permanent tracheostomy or functional laryngectomy
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Fig. 8 Pooled event rate of permanent gastrostomy tube for early stage SSCC treated with organ preservation surgery

TORS with RT is critical in determining the therapeutic
algorithm that can yield better functional outcomes in
early stage SSCC patient. Many studies were ruled out as
part of our protocol due to the stratification of results with
respect to laryngeal subsite and staging criteria (including
advanced stage disease). The method in which functional
results are reported, is often less rigorous than the reporting of survival and locoregional control. The use of objective measures and validated tools was limited and not
consistent across studies.
Traditionally, studies comparing surgery and radiation
have been challenging to accrue patients to. Ongoing
efforts comparing OPS to RT for oropharyngeal cancer are
underway and actively accruing [60, 61], demonstrating that
a head-to-head comparison of surgery and radiation is a
possibility for patients with early stage supraglottic cancer.
High level of evidence is important in the development of
treatment guidelines for patients with early stage disease
that have a surprisingly poor prognosis, compared to other
early stage head and neck cancers. Traditionally, OPS has
been seen as an option with poor functional outcomes. We
did not find evidence to support one modality being better
than another with respect to functional outcomes.

Conclusions
There is an overall paucity of literature available regarding
functional outcomes in the treatment of early stage SSCC
patients, the majority of which is moderate in overall
quality and retrospective in nature. The majority of the
data does not reflect the treatment algorithms of today,
with the introduction of focused radiation therapies and
endoscopic surgical approaches. Changes to treatment
algorithms have not been reflected in head-to-head studies
examining the functional outcomes. The outcome measures reported have significant heterogeneity in the
current literature, which limits the ability to draw definitive conclusions.
Moving forward, we propose that aspiration, intractable aspiration intervention, permanent gastrostomy
tube requirements, and objective quality of life scales as
objective measures that should be included in future research on this topic. Future studies and research should
include well designed prospective trials with rigorous
reporting of outcome measures.
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